# Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/aha/123773) · 2026-11-07 · Medicine
Page: https://themorning.science/story/ziltivekimab-falls-short-for-cutting-cardiovascular-events-in-ascvd-ckd-031ae5c825255ea3
Kind: research · Impact: medium

## In brief

- Ziltivekimab, a monoclonal antibody, lowered inflammatory markers in the trial.
- It did not reduce cardiovascular events in patients with ASCVD and CKD.

## Why it matters

The trial shows that lowering inflammatory markers with ziltivekimab did not translate into fewer cardiovascular events, which matters for research into inflammation as a treatment target in cardiovascular disease.

## Coverage

- [Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD](https://www.medpagetoday.com/meetingcoverage/aha/123773) — MedPageToday.com - medical news for physicians, 2026-11-07

Tags: cardiovascular, inflammation, ckd, ascvd, clinical-trial

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science